Compare Amylx Pharmaceuticals Inc (AMLX) vs GXO Logistics Inc (GXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs GXO Logistics Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while GXO Logistics Inc trades at $47.96 (market cap $5.37B). The key difference: GXO Logistics Inc is far larger — about 2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | GXO | |
|---|---|---|
Market Cap | $2.64B | $5.37B |
Sector | Health | Industrials |
52-Week High | $24.19 | $65.59 |
52-Week Low | $7.82 | $45.52 |
Enterprise Value | $2.39B | $10.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
GXO Logistics trades at $47.98, up 2.17% today, with a bearish technical signal but strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.59 exceeding expectations, and revenue growth to $13.6B in 2026. Recent news highlights CEO commentary on data center growth and business transfers, while margins face pressure.
Outlook is mixed: high P/E of 41.3 suggests premium valuation, but low P/S of 0.4 and 88.9% buy ratings from analysts signal upside potential to a $65.67 consensus target. Risks include margin stagnation and competitive logistics market, requiring monitoring of profit expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
